NCT06203496 Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs
| NCT ID | NCT06203496 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Caen |
| Condition | Glioma, Malignant |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of intracellular signalling pathways that govern cellular behaviour (Komatsu et al., 2023). They are widely implicated in oncogenesis, and in particular in mechanisms promoting cell migration, invasion and proliferation (Romano et al., 2021). Several preliminary studies have shown that serum levels of pro-oncogenic microRNAs correlate with tumor rates in gliomas (Jones et al., 2021; Levallet et al., 2022; Morokoff et al., 2020). Morokoff's study showed encouraging but insufficient results on the possibility of using microRNAs to differentiate radionecrosis versus recurrence. These results need to be consolidated prospectively, with homogeneous samples taken from all patients. The aim of this study is to describe the evolution over time of plasma levels of pro-oncogenic microRNAs, after surgery for grade 4 glioma, in order to assess whether they can be used to identify false-positive recurrences on MRI (radionecrosis).
Eligibility Criteria
Inclusion Criteria: * Major patient * Grade 4 diffuse glioma * Surgery in the neurosurgery department of Caen University Hospital * Patient affiliated to a social security scheme * Patient followed at Caen University Hospital * No opposition from patient Exclusion Criteria: * \- Patients who underwent biopsy (lack of material for study, limited interest of monitoring for these patients without surgical excision). * Patients with grade 1 circumscribed glioma or grade 2 or 3 diffuse glioma. * Other non-glial histologies, glioneuronal histology * Minor patients * Patient not affiliated to a social security scheme * A minor under guardianship or protection * Patient opposed to study
Frequently Asked Questions
Who can join the NCT06203496 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioma, Malignant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06203496 currently recruiting?
Yes, NCT06203496 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Caen to inquire about joining.
Where is the NCT06203496 trial being conducted?
This trial is being conducted at Caen, France.
Who is sponsoring the NCT06203496 clinical trial?
NCT06203496 is sponsored by University Hospital, Caen. The trial plans to enroll 60 participants.